Literature DB >> 27036860

SFE/SFHTA/AFCE consensus on primary aldosteronism, part 4: Subtype diagnosis.

Stéphane Bardet1, Bernard Chamontin2, Claire Douillard3, Jean-Yves Pagny4, Anne Hernigou5, Francis Joffre6, Pierre-François Plouin7, Olivier Steichen8.   

Abstract

To establish the cause of primary aldosteronism (PA), it is essential to distinguish unilateral from bilateral adrenal aldosterone secretion, as adrenalectomy improves aldosterone secretion and controls hypertension and hypokalemia only in the former. Except in the rare cases of type 1 or 3 familial hyperaldosteronism, which can be diagnosed genetically and are not candidates for surgery, lateralized aldosterone secretion is diagnosed on adrenal CT or MRI and adrenal venous sampling. Postural stimulation tests and (131)I-norcholesterol scintigraphy have poor diagnostic value and (11)C-metomidate PET is not yet available. We recommend that adrenal CT or MRI be performed in all cases of PA. Imaging may exceptionally identify adrenocortical carcinoma, for which the surgical objectives are carcinologic, and otherwise shows either normal or hyperplastic adrenals or unilateral adenoma. Imaging alone carries a risk of false positives in patients over 35 years of age (non-aldosterone-secreting adenoma) and false negatives in all patients (unilateral hyperplasia). We suggest that all candidates for surgery over 35 years of age undergo adrenal venous sampling, simultaneously in both adrenal veins, without ACTH stimulation, to confirm the unilateral form of the hypersecretion. Sampling results should be confirmed on adrenal vein cortisol assay showing a concentration at least double that found in peripheral veins. Aldosterone secretion should be considered lateralized when aldosterone/cortisol ratio on the dominant side is at least 4-fold higher than contralaterally. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Adrenal vein sampling; Adénome sécrétant de l’aldostérone; Aldosterone; Aldosterone-secreting adenoma; Aldosteronism; Aldostérone; Cathétérisme veineux surrénal; Hyperaldostéronisme primaire; Primary

Mesh:

Substances:

Year:  2016        PMID: 27036860     DOI: 10.1016/j.ando.2016.01.008

Source DB:  PubMed          Journal:  Ann Endocrinol (Paris)        ISSN: 0003-4266            Impact factor:   2.478


  4 in total

Review 1.  Familial hyperaldosteronism type III a novel case and review of literature.

Authors:  Natividad Pons Fernández; Francisca Moreno; Julia Morata; Ana Moriano; Sara León; Carmen De Mingo; Ángel Zuñiga; Fernando Calvo
Journal:  Rev Endocr Metab Disord       Date:  2019-03       Impact factor: 6.514

2.  The Quality of Clinical Practice Guidelines and Consensuses on the Management of Primary Aldosteronism: A Critical Appraisal.

Authors:  Zhe Meng; Liang Zhou; Zhe Dai; Chang Xu; Guofeng Qian; Mou Peng; Yuchun Zhu; Joey S W Kwong; Xinghuan Wang
Journal:  Front Med (Lausanne)       Date:  2020-05-05

Review 3.  Recent Development toward the Next Clinical Practice of Primary Aldosteronism: A Literature Review.

Authors:  Yuta Tezuka; Yuto Yamazaki; Yasuhiro Nakamura; Hironobu Sasano; Fumitoshi Satoh
Journal:  Biomedicines       Date:  2021-03-17

4.  Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension: ADERADHTA, a pilot study.

Authors:  Béatrice Bouhanick; Marie C Delchier; Séverine Lagarde; Romain Boulestreau; Claude Conil; Philippe Gosse; Hervé Rousseau; Benoit Lepage; Pascale Olivier; Panteleimon Papadopoulos; Hervé Trillaud; Antoine Cremer
Journal:  J Hypertens       Date:  2021-04-01       Impact factor: 4.776

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.